Patents by Inventor Thierry Francois Alain Jean Jousseaume

Thierry Francois Alain Jean Jousseaume has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • (R)-8-(1-((3-fluorophenyl)amino)ethyl)-N-(2-hydroxyethyl)-2-morpholinoquinoxaline-6-carboxamide for inhibiting phosphoinositide-3-kinase activity
    Patent number: 11267804
    Abstract: The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: November 12, 2019
    Date of Patent: March 8, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick Rene Angibaud, Olivier Alexis Georges Querolle, Didier Jean-Claude Berthelot, Christophe Meyer, Matthieu Philippe Victor Willot, Lieven Meerpoel, Thierry Francois Alain Jean Jousseaume
  • Quinoxaline and pyridopyrazine derivatives as PI3K-beta inhibitors
    Patent number: 11130751
    Abstract: The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: September 28, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick René Angibaud, Olivier Alexis Georges Querolle, Didier Jean-Claude Berthelot, Christophe Meyer, Matthieu Philippe Victor Willot, Lieven Meerpoel, Thierry François Alain Jean Jousseaume
  • QUINOXALINE AND PYRIDOPYRAZINE DERIVATIVES AS PI3K-BETA INHIBITORS
    Publication number: 20200181132
    Abstract: The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: March 29, 2018
    Publication date: June 11, 2020
    Inventors: Patrick Rene Angibaud, Olivier, Alexis Georges QUEROLLE, Didier Jean-Claude BERTHELOT, Christophe MEYER, Matthieu Philippe, Victor WILLOT, Lieven MEERPOEL, Thierry, François Alain, Jean JOUSSEAUME
  • QUINOXALINE AND PYRIDOPYRAZINE DERIVATIVES AS A PI3KB INHIBITORS
    Publication number: 20200079763
    Abstract: The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: November 12, 2019
    Publication date: March 12, 2020
    Inventors: Patrick Rene Angibaud, Olivier Alexis Georges Querolle, Didier Jean-Claude Berthelot, Christophe Meyer, Matthieu Philippe Victor Willot, Lieven Meerpoel, Thierry Francois Alain Jean Jousseaume
  • Quinoxaline and pyridopyrazine derivatives as PI3K? inhibitors
    Patent number: 10526316
    Abstract: The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: January 7, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Patrick Rene Angibaud, Olivier Alexis Georges Querolle, Didier Jean-Claude Berthelot, Christophe Meyer, Matthieu Philippe Victor Willot, Lieven Meerpoel, Thierry Francois Alain Jean Jousseaume
  • Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine derivatives and 2,3-dihydro-1H-imidazo[1,2-b]pyrazole derivatives as ROS1 inhibitors
    Patent number: 10342795
    Abstract: The present invention relates to substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine derivatives and 2,3-dihydro-1H-imidazo[1,2-b]pyrazole derivatives of formula (I) and also compounds of formula (I?) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as ROS1 inhibitors. The invention further relates to processes for preparing novel compounds of the present invention, pharmaceutical compositions comprising compounds of the present invention as an active ingredient as well as the use of compounds of the present invention as a medicament.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: July 9, 2019
    Assignee: Janssen Pharmaceutica NV
    Inventors: Laurence Anne Mevellec, Matthieu Ludovic Jeanty, Thierry Francois Alain Jean Jousseaume
  • Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives as Ros1 inhibitors
    Patent number: 10280170
    Abstract: The present invention relates to substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives of formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as ROS1 inhibitors. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: May 7, 2019
    Assignee: Janssen Pharmaceutica NV
    Inventors: Laurence Anne Mevellec, Elisabeth Therese Jeanne Pasquier, Sophie Descamps, Guillaume Jean Maurice Mercey, Berthold Wroblowski, Jorge Eduardo Vialard, Lieven Meerpoel, Matthieu Ludovic Jeanty, Thierry Francois Alain Jean Jousseaume
  • QUINOXALINE AND PYRIDOPYRAZINE DERIVATIVES AS PI3KB INHIBITORS
    Publication number: 20190062311
    Abstract: The present invention relates to substituted quinoxaline and pyridopyrazine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as pI3K? inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: October 7, 2016
    Publication date: February 28, 2019
    Inventors: Patrick Rene Angibaud, Olivier Alexis Georges Querolle, Didier Jean-Claude Berthelot, Christophe Meyer, Matthieu Philippe Victor Willot, Lieven Meerpoel, Thierry Francois Alain Jean Jousseaume
  • SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AND 2,3-DIHYDRO-1H-IMIDAZO[1,2-b]PYRAZOLE DERIVATIVES AS ROS1 INHIBITORS
    Publication number: 20170173014
    Abstract: The present invention relates to substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine derivatives and 2,3-dihydro-1H-imidazo[1,2-b]pyrazole derivatives of formula (I) and also compounds of formula (I?) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as ROS1 inhibitors. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: March 26, 2015
    Publication date: June 22, 2017
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Laurence Anne Mevellec, Matthieu Ludovic Jeanty, Thierry Francois Alain Jean Jousseaume
  • SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS
    Publication number: 20170174690
    Abstract: The present invention relates to substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives of formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as ROS1 inhibitors. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Application
    Filed: March 26, 2015
    Publication date: June 22, 2017
    Applicant: Janssen Pharmaceutica NV
    Inventors: Laurence Anne Mevellec, Elisabeth Therese Jeanne Pasquier, Sophie Descamps, Guillaume Jean Maurice Mercey, Berthold Wroblowski, Jorge Eduardo Vialard, Lieven Mrrtpoel, Matthieu Ludovic Jeanty, Thierry Francois Alain Jean Jousseaume